

Application Serial No. 10/067,857  
Preliminary Amendment dated 28 October 2003

*SEQUENCE LISTING*

Please substitute the attached pages 1-5 of Sequence Listing submitted herewith for the five (5) pages of sequence listing originally filed with the application.

*REMARKS*

The specification has been amended to insert the current status of the parent application.

A substitute Sequence Listing has been provided to conform the definitions of the Xaa amino acid residues to the description found in the specification at page 3, lines 19-32 for SEQ ID NO:2. A computer readable form of the substitute Sequence Listing is submitted with a Statement Pursuant to 37 C.F.R. § 1.821(f). No new matter is introduced by this substitute Sequence Listing.

The claims have been amended to change the “substantially pure” language to “isolated.”

Claim 1 has also been amended to correct the sequence of the generic sequence in part (b) to conform with the sequence found on page 3, line 17 and to conform to the sequence of SEQ ID NO:2. Claim 1 has further been amended to correct the reference of the contulakin-G analog in part (e) and to correct the amino acid positions in part (f). Support for this latter amendment can be found at page 4, lines 13-14.

Claims 2-6 have been amended to specify that the conopeptide is contulakin-G of part (a).


Claims 7 and 8 have been amended to specify that the conopeptide is selected from the group of peptides list in the claims.

Claims 4, 8, 11, 14, 17, 20, 23 and 26 have been amended to more clearly set forth the nature of the glycan. Specifically, the language “R<sub>1</sub> is an amino acid capable of being derivatized with a glycan either chemically or enzymatically” has been replaced by language specifying the amino acid and the linkage X. For example, in claim 4, R<sub>1</sub> has been specified as “Thr” and X as “O” since the only amino acid of the contulakin-G of (a) that contains a glycan is Thr and the linkage is O. Support for this language can be found in, for example, the claims as filed which specified an O-glycan modified Thr, an O-glycan modified Ser, an S-glycan modified Cys, an N-modified Asn or an N-modified Lys.

It is submitted that none of these amendments constitute new matter, and their entry is requested.

Application Serial No. 10/067,857  
Preliminary Amendment dated 28 October 2003

It is submitted that the present claims satisfy the requirements of the patent statutes and are patentable over the prior art. Favorable consideration of this application is requested. The Examiner is invited to telephone the undersigned in order to expedite prosecution of the present application.

RESPECTFULLY SUBMITTED,					
<i>Name and Reg. Number</i>	Jeffrey L. Ihnen, Registration No. 28,957				
<i>Signature</i>				<i>Date</i>	28 October 2003
<i>Address</i>	Rothwell, Figg, Ernst & Manbeck, pc Suite 800, 1425 K Street, N.W.				
<i>City</i>	Washington	<i>State</i>	D.C.	<i>Zip Code</i>	20005
<i>Country</i>	U.S.A.	<i>Telephone</i>	202-783-6040	<i>Fax</i>	202-783-6031